+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Recent advances in therapy for gastrointestinal stromal tumors

Recent advances in therapy for gastrointestinal stromal tumors

Current Oncology Reports 9(3): 165-169

Sarcomas comprise less than 1% of all cancers. Gastrointestinal stromal tumor (GIST) is the most common form of sarcoma and can vary in size and clinical outcome from an incidental finding at operation to life-threatening metastatic disease. Surgery is the standard of care for primary disease, and the oral drug imatinib is the standard of care for metastatic disease. Sunitinib was approved in the United States in early 2006 for GIST that is refractory to imatinib. The pathology of GIST, surgical options for primary and metastatic disease, and findings leading to the use of imatinib and sunitinib for GIST are highlighted in this review.

(PDF emailed within 0-6 h: $19.90)

Accession: 055399445

Download citation: RISBibTeXText

PMID: 17430686

DOI: 10.1007/s11912-007-0017-0

Related references

Recent advances in the management of gastrointestinal stromal tumors. F1000 Medicine Reports 2: -, 2010

Recent advances in the treatment of gastrointestinal stromal tumors. Therapeutic Advances in Medical Oncology 6(3): 115-127, 2014

Recent advances in the management of gastrointestinal stromal tumors. Current Oncology Reports 5(4): 288-294, 2003

Gastrointestinal stromal tumors: recent advances in understanding of their biology. Human Pathology 30(10): 1213-1220, 1999

Advances in adjuvant therapy of gastrointestinal stromal tumors. Current Oncology Reports 14(4): 327-332, 2012

Recent advances in cell biology, diagnosis, and therapy of gastrointestinal stromal tumor (GIST). Cancer Biology & Therapy 3(3): 251-258, 2004

Gastrointestinal stromal tumours: clinical overview, surgery and recent advances in imatinib mesylate therapy. European Journal of Surgical Oncology 33(8): 942-950, 2007

Combination therapy for gastrointestinal stromal tumors: evidence from recent clinical trials. Clinical Investigation 1(6): 825-836, 2011

Recent advances in systemic therapy for gastrointestinal neuroendocrine tumors. Current Opinion in Oncology 11(1): 32-37, 1999

Recent advances in diagnosis and therapy of neuroendocrine tumors of the gastrointestinal tract. Current Opinion in Oncology 9(1): 68-74, 1997

Recent advances in managing gastrointestinal stromal tumor. F1000research 6: 1689-1689, 2017

Dedifferentiated gastrointestinal stromal tumor: Recent advances. Annals of Diagnostic Pathology 2019, 2019

Diagnostic morphological features of PDGFRA-mutated gastrointestinal stromal tumors: molecular genetic and histologic analysis of 60 cases of gastric gastrointestinal stromal tumors. Annals of Diagnostic Pathology 11(1): 27-33, 2007

Recent advances and novel agents for gastrointestinal stromal tumor (GIST). Journal of Hematology & Oncology 5: 21-21, 2012

Gastrointestinal stromal tumor: recent advances in pathology and genetics. Pathology International 65(1): 9-18, 2015